

**REMARKS*****Claim Amendments***

After entry of this amendment, claims 30, 71, 76, 85-88, 96, 98-100 103-114, 117-119 and 123-128 will be pending in this application.

Claims 30, 85, 103-105, 107-109 and 117-119 have been amended. Claims 123-128 have been added. These amendments do not add any new matter to the specification. See, e.g., page 16, lines 10-13 and 17-23; page 25, lines 10-12; page 28, lines 17-19; and Examples 1 and 2.

Claims 75, 89, 93, 95, 101-102, 115, 116 and 120-122 have been cancelled without prejudice. Applicants reserve the right to file a continuing application including subject matter that has been cancelled in this application.

***Telephonic Interview***

Applicants thank Examiner Canella for participating in a telephonic interview on April 11, 2006 to discuss the outstanding rejections. The claim amendments made herein are a result of this interview, and Applicants appreciate the Examiner's assistance.

***Rejections Under 35 U.S.C. §112, first paragraph******Written Description***

Claims 103-106, 108, 109 and 122 are rejected as allegedly failing to comply with the written description requirement. According to the Examiner, "[t]he specification does not provide support for the broad method wherein said T-cells are cytotoxic T-cells, or wherein said T-cells are reactive with at least one other epitope within the tumor associated antigen." However, the Examiner acknowledges that "[t]he specification describes a method wherein the administration of antibody-tumor antigen complex induces antibodies which are reactive with at least one other epitope associated with the tumor associated antigen (Example 1) and the concurrent activation of cytotoxic T-cells in the case of CA125 (Example 2)."

Claims 103-106, 108, 109 and 122 have been amended to recite a method that results in the induction of cytotoxic T cells reactive with CA125. This amendment obviates the Examiner's rejection.

***Enablement***

The Examiner objects to claims 30, 71, 75, 76, 85, 87, 89, 93 and 95-122 as allegedly failing to meet the enablement requirement. The Examiner states that the specification "while being enabling for a method of treating an oncological disease comprising administering to a host a complex formed from CA125 and a monoclonal antibody or antigen-binding fragment thereof that binds CA125, . . . does not reasonably provide enablement for the administration of any other complex of a soluble tumor antigen and a monoclonal antibody or antigen binding fragment thereof."

The claims have been amended to recite methods of treating an oncological disease comprising administering a complex formed from CA125 and an antibody or antigen binding fragment thereof that binds CA125. This amendment obviates the Examiner's rejection.

***Conclusion***


In view of the above amendments, Applicants believe the pending application is in condition for allowance.

Other than the enclosed fee for the three month extension of time, Applicants believe no fee is due with this response. However, if an additional fee is due, please charge our Deposit Account No. 18-1945, under Order No. AREX-P02-004 from which the undersigned is authorized to draw.

Dated: April 28, 2006

Respectfully submitted,

By



Gloria Fuentes

Registration No.: 47,580  
ROPES & GRAY LLP  
One International Place  
Boston, Massachusetts 02110-2624  
(617) 951-7000  
(617) 951-7050 (Fax)  
Attorneys/Agents For Applicant